Acumen Pharmaceuticals, Inc. (ABOS) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights
November 14, 2022 4:01 PM ESTINTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimers disease continues to progress
Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023
ACU193 was granted Fast Track designation from the U.S. FDA for the treatment of early Alzheimers disease
Cash, cash equivalents and marketable securities of $200.2 million as of Sept. 30, 2022 expected to be sufficient to support clinical and operational goals through 2025
Company to host conference call and webcast today at... More
